BUZZ-百健因 FDA 批准更高剂量的 Spinraza 用于治疗肌肉疾病而上涨

路透中文
Mar 30
BUZZ-百健因 FDA 批准更高剂量的 Spinraza 用于治疗肌肉疾病而上涨

3月30日 - ** 制药公司百健BIIB.O股价盘前上涨1.75%至187.06美元

** 该公司称,美国食品和药物管理局批准了Spinraza的高剂量版本,用于治疗脊髓性肌萎缩症,这是一种罕见的遗传性疾病,会导致重症肌无力并可能致命。

** 该公司称,新剂量既可用于新患者,也可用于已在服用Spinraza的患者

** 该公司称,批准的依据是一项后期研究,研究显示婴儿的运动和运动功能优于未接受治疗的患者,总体安全性与旧剂量相似

** 公司称高剂量版本已在欧盟、瑞士和日本获得批准,并将于未来几周在美国上市

** 2025 年股价上涨约 15%

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10